Gsa Capital Partners LLP Igm Biosciences, Inc. Call Options Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IGMS
# of Institutions
66Shares Held
14.9MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.1MShares$5.33 Million0.05% of portfolio
-
Siren, L.L.C. New York, NY3.26MShares$4.23 Million0.19% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.84 Million0.4% of portfolio
-
Black Rock Inc. New York, NY883KShares$1.15 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY855KShares$1.11 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $37.7M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...